JP2006508120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508120A5 JP2006508120A5 JP2004551572A JP2004551572A JP2006508120A5 JP 2006508120 A5 JP2006508120 A5 JP 2006508120A5 JP 2004551572 A JP2004551572 A JP 2004551572A JP 2004551572 A JP2004551572 A JP 2004551572A JP 2006508120 A5 JP2006508120 A5 JP 2006508120A5
- Authority
- JP
- Japan
- Prior art keywords
- retinal
- formulation
- disease
- condition
- retinopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000002207 retinal effect Effects 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 208000032253 retinal ischemia Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 238000013532 laser treatment Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229950005455 eliprodil Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229950000754 nipradilol Drugs 0.000 description 2
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GGUSQTSTQSHJAH-FQEVSTJZSA-N (R)-eliprodil Chemical compound C([C@H](O)C=1C=CC(Cl)=CC=1)N(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-FQEVSTJZSA-N 0.000 description 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960004771 levobetaxolol Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical class [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42557602P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/033873 WO2004043348A2 (en) | 2002-11-12 | 2003-10-27 | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508120A JP2006508120A (ja) | 2006-03-09 |
| JP2006508120A5 true JP2006508120A5 (https=) | 2006-07-13 |
Family
ID=32313019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551572A Withdrawn JP2006508120A (ja) | 2002-11-12 | 2003-10-27 | 眼の変性疾患を処置するためのヒストンデアセチラーゼインヒビター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040092431A1 (https=) |
| EP (1) | EP1562592A4 (https=) |
| JP (1) | JP2006508120A (https=) |
| KR (1) | KR20050074547A (https=) |
| CN (1) | CN1711086A (https=) |
| AU (1) | AU2003286686B2 (https=) |
| BR (1) | BR0316163A (https=) |
| CA (1) | CA2504226A1 (https=) |
| MX (1) | MXPA05004738A (https=) |
| RU (1) | RU2324483C2 (https=) |
| WO (1) | WO2004043348A2 (https=) |
| ZA (1) | ZA200503230B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN1711086A (zh) * | 2002-11-12 | 2005-12-21 | 爱尔康公司 | 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂 |
| US20080004311A1 (en) * | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| JP2006512318A (ja) * | 2002-11-12 | 2006-04-13 | アルコン，インコーポレイテッド | 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
| US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| GB2417682A (en) * | 2004-08-18 | 2006-03-08 | Univ East Anglia | Histone deacetylse inhibitor for treating connective tissue disorders |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| CA2596015A1 (en) | 2005-02-14 | 2006-08-24 | Sampath K. Anandan | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
| US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| AU2006272497B2 (en) * | 2005-07-27 | 2012-07-19 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
| JP2008266321A (ja) * | 2007-03-28 | 2008-11-06 | Santen Pharmaceut Co Ltd | フェニレンジアミン誘導体を有効成分とする眼圧下降剤 |
| EP2135620A4 (en) * | 2007-03-28 | 2010-12-29 | Santen Pharmaceutical Co Ltd | AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE |
| WO2008117862A1 (ja) | 2007-03-28 | 2008-10-02 | Santen Pharmaceutical Co., Ltd. | ウレア構造を有する新規ピリジンカルボン酸（２－アミノフェニル）アミド誘導体 |
| US8198271B2 (en) | 2008-05-23 | 2012-06-12 | Santen Pharmaceutical Co., Ltd. | Thiophenediamine derivative having urea structure |
| US8754050B2 (en) * | 2010-05-27 | 2014-06-17 | The Regents Of The University Of Colorado | Macrocyclic compounds useful as inhibitors of histone deacetylases |
| CN107362148B (zh) * | 2017-07-27 | 2020-04-21 | 东曜药业有限公司 | 一种治疗肿瘤的药物组合物及其制备方法和应用 |
| CN116348103A (zh) * | 2020-06-11 | 2023-06-27 | 纽约市哥伦比亚大学理事会 | 用于用组蛋白脱乙酰酶(hdac)抑制剂曲古抑菌素a及其衍生物预防和治疗近视的方法和组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) * | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| DE1300150T1 (de) * | 1988-09-06 | 2003-09-18 | Pharmacia Ab, Stockholm | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5464866A (en) * | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| HUP0003880A3 (en) * | 1997-10-06 | 2001-11-28 | American Cyanamid Co Madison | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same |
| AUPP505798A0 (en) * | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
| JP2004516328A (ja) * | 2000-12-22 | 2004-06-03 | ヒャン ウー リー | アピシジン誘導体、その合成方法、及び該誘導体を含む抗癌剤組成物 |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US7154002B1 (en) * | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) * | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20080004311A1 (en) * | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| CN1711086A (zh) * | 2002-11-12 | 2005-12-21 | 爱尔康公司 | 用于治疗眼的退化性疾病的组蛋白脱乙酰酶抑制剂 |
| US8034768B2 (en) * | 2007-06-22 | 2011-10-11 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by histone deacetylase inhibitors |
-
2003
- 2003-10-27 CN CNA2003801029350A patent/CN1711086A/zh active Pending
- 2003-10-27 RU RU2005118108/14A patent/RU2324483C2/ru not_active IP Right Cessation
- 2003-10-27 CA CA002504226A patent/CA2504226A1/en not_active Abandoned
- 2003-10-27 US US10/694,309 patent/US20040092431A1/en not_active Abandoned
- 2003-10-27 MX MXPA05004738A patent/MXPA05004738A/es active IP Right Grant
- 2003-10-27 AU AU2003286686A patent/AU2003286686B2/en not_active Ceased
- 2003-10-27 BR BR0316163-3A patent/BR0316163A/pt not_active IP Right Cessation
- 2003-10-27 US US10/531,747 patent/US20070088045A1/en not_active Abandoned
- 2003-10-27 KR KR1020057008066A patent/KR20050074547A/ko not_active Ceased
- 2003-10-27 EP EP03777895A patent/EP1562592A4/en not_active Withdrawn
- 2003-10-27 JP JP2004551572A patent/JP2006508120A/ja not_active Withdrawn
- 2003-10-27 WO PCT/US2003/033873 patent/WO2004043348A2/en not_active Ceased
-
2005
- 2005-04-21 ZA ZA200503230A patent/ZA200503230B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508120A5 (https=) | ||
| US20040216749A1 (en) | Vasomodulation during glaucoma surgery | |
| CA2502437C (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| Brown et al. | ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery | |
| CA2496797C (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin | |
| KR100452715B1 (ko) | 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도 | |
| EP1265601B1 (en) | Method for treating ocular pain | |
| AU2003286686B2 (en) | Histone deacetylase inhibitors for treating degenerative diseases of the eye | |
| MX2009000885A (es) | Soluciones oftalmicas. | |
| CA2807084C (en) | Preservative free brimonidine and timolol solutions | |
| US5652272A (en) | Ophthalmic preparations for reducing intraocular pressure | |
| AU2001238313A1 (en) | Method for treating ocular pain | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| EP0672417A1 (en) | Reduction of elevated intraocular pressure | |
| ES2210018T3 (es) | Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma. | |
| JP2005516017A (ja) | 向上した薬物動態特性を示す医薬コンジュゲート | |
| US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
| CA2414586C (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
| WO2019131901A1 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
| WO2007090134A2 (en) | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma | |
| JP2004536847A5 (https=) | ||
| EP0608604A1 (en) | Ajmaline to reduce elevated intraocular pressure | |
| Simsek et al. | Effects of 0.5% and 0.25% apraclonidine on postoperative intraocular hypertension after cataract extraction | |
| Taniguchi et al. | A risk-benefit assessment of drugs used in the management of glaucoma | |
| JPH02504150A (ja) | 交感神経刺激剤及びベーター１選択性ベータ遮断薬の組合せを含む抗緑内障組成物 |